Home    Back

Biib092    (DrugBank: -)

3 diseases
IDDisease name (Link within this page)Number of trials
5Progressive supranuclear palsy7
7Corticobasal degeneration1
127Frontotemporal lobar degeneration1

5. Progressive supranuclear palsy    [ 82 clinical trials,   107 drugs,   (DrugBank: 36 drugs),   60 drug target genes,   90 drug target pathways]
Searched query = "Progressive supranuclear palsy", "PSP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
7 / 82 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2016-002554-21-GR
(EUCTR)		09/03/201802/01/2018Study of BIIB092 in Participants With Progressive Supranuclear PalsyA Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants with Progressive Supranuclear Palsy Progressive supranuclear palsy
MedDRA version: 20.0;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Biogen Idec Research LimitedNULLNot Recruiting Female: yes
Male: yes		396Phase 2United States;Greece;Spain;Austria;Russian Federation;United Kingdom;Italy;France;Canada;Australia;Germany;Japan;Korea, Republic of
2EUCTR2016-002554-21-DE
(EUCTR)		18/08/201719/04/2017A study of BIIB092 in participants with Progressive Supranuclear PalsyA Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB0092 in Participants with Progressive Supranuclear Palsy Progressive supranuclear palsy
MedDRA version: 21.1;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Code: BIIB092
INN or Proposed INN: BIIB092
Other descriptive name: BIIB092		Biogen Idec Research LimitedNULLNot RecruitingFemale: yes
Male: yes		459Phase 2United States;Greece;Spain;Austria;Russian Federation;Italy;United Kingdom;France;Canada;Australia;Germany;Japan;Korea, Republic of
3EUCTR2016-002554-21-GB
(EUCTR)		21/07/201710/04/2017Study of BIIB092 in Participants With Progressive Supranuclear PalsyA Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants with Progressive Supranuclear Palsy Progressive supranuclear palsy
MedDRA version: 21.1;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Code: BIIB092
INN or Proposed INN: BIIB092
Other descriptive name: BIIB092		Biogen Idec Research LimitedNULLNot RecruitingFemale: yes
Male: yes		459Phase 2Canada;Australia;Germany;Japan;Korea, Republic of;United States;Greece;Spain;Austria;Russian Federation;United Kingdom;Italy;France
4EUCTR2016-002554-21-AT
(EUCTR)		30/06/201720/04/2017Study of BIIB092 in Participants With Progressive Supranuclear PalsyA Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants with Progressive Supranuclear Palsy Progressive supranuclear palsy
MedDRA version: 21.1;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Code: BIIB092
INN or Proposed INN: BIIB092
Other descriptive name: BIIB092		Biogen Idec Research LimitedNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		459Phase 2United States;Greece;Spain;Austria;Russian Federation;United Kingdom;Italy;France;Canada;Australia;Germany;Japan;Korea, Republic of
5NCT03068468
(ClinicalTrials.gov)		June 1, 201727/2/2017Study of BIIB092 in Participants With Progressive Supranuclear PalsyA Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants With Progressive Supranuclear PalsySupranuclear Palsy, ProgressiveDrug: BIIB092;Drug: PlaceboBiogenNULLTerminated41 Years86 YearsAll490Phase 2United States;Australia;Austria;Canada;France;Germany;Greece;Italy;Japan;Korea, Republic of;Russian Federation;Spain;United Kingdom
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
6NCT02658916
(ClinicalTrials.gov)		February 22, 201613/1/2016Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PSP) Who Participated in CN002003A Multicenter, Open-Label, Long-Term Treatment Study of Intravenously Administered BIIB092 in Patients With Progressive Supranuclear Palsy Who Participated in Study CN002003Supranuclear Palsy, ProgressiveDrug: BIIB092BiogenNULLTerminated41 Years86 YearsAll47Phase 1United States
7NCT02460094
(ClinicalTrials.gov)		October 2, 201520/5/2015Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear PalsyA Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of Intravenously Administered BMS-986168 in Patients With Progressive Supranuclear PalsyProgressive Supranuclear PalsyDrug: BIIB092;Drug: PlaceboBiogenNULLCompleted41 Years86 YearsAll48Phase 1United States

Back to top


7. Corticobasal degeneration    [ 16 clinical trials,   33 drugs,   (DrugBank: 11 drugs),   6 drug target genes,   13 drug target pathways]
Searched query = "Corticobasal degeneration", "Corticobasal syndrome", "CBD"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 16 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT03658135
(ClinicalTrials.gov)		September 12, 201813/8/2018BIIB092 in Primary Tauopathies: CBS, nfvPPA, sMAPT, and TESA Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Parallel Cohort Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of Intravenously Infused BIIB092 in Patients With Four Different Primary Tauopathy SyndromesPrimary Tauopathies;Corticobasal Degeneration Syndrome;Frontotemporal Lobar Degeneration With Tau Inclusions;MAPT Mutation Carriers, Symptomatic;Traumatic Encephalopathy Syndrome;Nonfluent Aphasia, ProgressiveDrug: BIIB092;Other: PlaceboUniversity of California, San FranciscoNULLTerminated35 Years80 YearsAll22Phase 1United States

127. Frontotemporal lobar degeneration    [ 74 clinical trials,   83 drugs,   (DrugBank: 28 drugs),   29 drug target genes,   99 drug target pathways]
Searched query = "Frontotemporal lobar degeneration", "Frontotemporal dementia", "Semantic dementia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 74 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT03658135
(ClinicalTrials.gov)		September 12, 201813/8/2018BIIB092 in Primary Tauopathies: CBS, nfvPPA, sMAPT, and TESA Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Parallel Cohort Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of Intravenously Infused BIIB092 in Patients With Four Different Primary Tauopathy SyndromesPrimary Tauopathies;Corticobasal Degeneration Syndrome;Frontotemporal Lobar Degeneration With Tau Inclusions;MAPT Mutation Carriers, Symptomatic;Traumatic Encephalopathy Syndrome;Nonfluent Aphasia, ProgressiveDrug: BIIB092;Other: PlaceboUniversity of California, San FranciscoNULLTerminated35 Years80 YearsAll22Phase 1United States

Back to top